BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Tracking genomic aberrations of the androgen receptor (AR) in cast
 ration-resistant prostate cancer (CRPC) - Dr Gerhardt Attard\, Royal Marsd
 en Hospital\, London
DTSTART:20141118T120000Z
DTEND:20141118T130000Z
UID:TALK53731@talks.cam.ac.uk
CONTACT:Mala Jayasundera
DESCRIPTION:Next-generation sequencing of circulating plasma DNA from CRPC
  offers an opportunity to monitor tumor genomic aberrations over the cours
 e of the disease. These studies have identified multiple independent clone
 s with distinct genomic patterns showing complex dynamics over the lethal 
 course of prostate cancer\, partially related to treatment selection press
 ure. Clones harboring resistance-conferring AR mutations emerge in approxi
 mately 20% of patients treated with abiraterone and exogenous corticostero
 ids. These mutations are activated by ligands that persist in abiraterone-
 treated patients\, including by prednisolone or dexamethasone at clinicall
 y relevant doses\, and confer a survival advantage. Often sub-clones with 
 alternative genomic aberrations\, including AR amplification\, are also pr
 esent suggesting multiple mechanisms co-exist that lead to re-activation o
 f AR signaling. These data introduce a management paradigm requiring seque
 ntial monitoring of advanced prostate cancer patients with plasma and tumo
 r biopsies to ensure early discontinuation of agents when they become pote
 ntial disease drivers and identify therapeutic targets that will allow sel
 ection of the next best treatment.
LOCATION:CRUK CI Lecture Theatre
END:VEVENT
END:VCALENDAR